A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 in Subjects with Myelodysplastic Syndrome after Treatment with Hypomethylating Agents

ID Number 14-1586

Principal Investigator(s)
Lewis R Silverman

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called MEDI4736, to treat myelodysplastic syndrome (MDS).  An experimental drug is one that is being tested and is not available to buy on the market.  MEDI4736 is an antibody that is made in the laboratory.  In the human body, an antibody is a natural protein made by your immune system that binds other proteins and molecules to fight infection and its ill effects.  MEDI4736 is an experimental drug being tested in humans with MDS for the first time.

MEDI4736 binds to another protein in the body and may prevent cancer growth by helping certain blood cells of the immune system eliminate the cancer cells. The main purpose of this study is to determine the dose of MEDI4736 that is safe and tolerable in subjects such as you with this blood disorder.

Contact Information
Rosalie Odchimar
(212) 824-7309

Recruiting Patients: Yes